Geron Corporation
Every calculator, already run for GERN
Open the full toolkit →You have the numbers on GERN. Get the argument.
A written report on which of these readings actually decide the outcome for Geron Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering GERNAnalyst Price Target Disagreement for Geron Corporation
Wall Street's bull case implies +376% from the current price; the bear case implies +138%. A 238% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for GERN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatm…
GERN — frequently asked
Is GERN a buy right now?
Wall Street's consensus rating on Geron Corporation is none across 5 analysts, with a mean price target of $4.25 (+237% vs. the current $1.26). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is GERN's next earnings date?
Geron Corporation is next scheduled to report earnings around Nov 4, 2026. A full GERN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Geron Corporation?
Analysts covering Geron Corporation (GERN) range from a bear-case target of $3.00 to a bull-case high of $6.00, with a mean consensus target of $4.25 across 4 analysts. The spread of $3.00 (238% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Geron Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Geron Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GERN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Geron Corporation, in minutes. 3 free reports included with every account — no credit card required.